Publicacions en col·laboració amb investigadors/es de Jagiellonian University (9)

2024

  1. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

    Haematologica, Vol. 109, Núm. 3, pp. 895-905

2023

  1. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1383-1392

2022

  1. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884

2021

  1. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507

  2. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

  3. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573

2016

  1. The changing landscape of smoldering multiple myeloma: A european perspective

    Oncologist, Vol. 21, Núm. 3, pp. 333-342